JPMorgan analyst Jessica Fye noted that the disclosure that "less than a handful" of patients in Ionis Pharmaceuticals' (IONS) TTRRx phase 3 study in patients with familial amyloid polyneuropathy experienced concerning platelet drops, calling it a "clear risk" to monitor in the TTRRx program. Fye added that she is "very comfortable" giving Alnylam's (ALNY) TTR programs the edge in terms of their safety profile, pointing out that thrombocytopenia has not emerged as a safety concern in any of its ongoing programs. The firm keeps an Overweight rating on Alnylam, which is seen having multiple, near-term value creation events, and a Neutral rating on Ionis. Shares of Ionis, which announced this morning that partner GlaxoSmithKline (GSK) has decided not to initiate a Phase 3 outcome study that was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy, are down nearly 18% in morning trading.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).